<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Ophthalmol.</journal-id>
<journal-title>Frontiers in Ophthalmology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Ophthalmol.</abbrev-journal-title>
<issn pub-type="epub">2674-0826</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fopht.2023.1330335</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Ophthalmology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The BVI ISOPURE<sup>&#xae;</sup> 123 intraocular lens: a new hydrophobic preloaded extended monofocal IOL with intermediate vision correction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ansari</surname>
<given-names>Ejaz</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2095502"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Eye Ear and Mouth Unit, Maidstone &amp; Tunbridge Wells Hospitals</institution>, <addr-line>Kent</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Institute of Medical Sciences, Canterbury Christ Church University</institution>, <addr-line>Kent</addr-line>, <country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Yongwei Guo, Zhejiang University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Roberto Bellucci, Azienda Ospedaliera Universitaria Integrata Verona, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ejaz Ansari, <email xlink:href="mailto:e.ansari@nhs.net">e.ansari@nhs.net</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>3</volume>
<elocation-id>1330335</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>12</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Ansari</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Ansari</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The BVI ISOPURE<sup>&#xae;</sup> intraocular lens (IOL) (PhysIOL, Liege, Belgium) is a fully refractive, aspherical, monofocal lens based on isofocal technology. Isofocal technology provides cataract patients distance vision quality combined with improved unaided intermediate vision by accentuating the extended depth of field/focus (EDOF) effect whilst inducing minimal photic phenomena.</p>
<sec>
<title>Methods</title>
<p>PubMed, Web of Science, Scopus, and Google Scholar searches were conducted for published research articles featuring the ISOPURE 123 IOL.</p>
</sec>
<sec>
<title>Results</title>
<p>Excellent uncorrected and corrected binocular distance visual acuity of at least 20/25 can be achieved; uncorrected binocular intermediate vision of 20/25 or better in 81% and 50% at 80 cm and 66 cm, respectively, and 42% binocular near vision of 20/40 or better can be achieved. The defocus curve showed good visual acuity at far and intermediate distances with a depth of focus value of 1.50 D. Photic phenomena are minimal compared to other EDOF IOLs. Excellent contrast sensitivity was maintained compared to a standard monofocal IOL.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Studies show that this isofocal optic design IOL provides excellent visual performance for far vision and functional intermediate vision with an increased range of vision with few photic phenomena. This lens is an effective option for providing functional intermediate vision and correcting aphakia.</p>
</sec>
</abstract>
<kwd-group>
<kwd>extended depth of field/focus</kwd>
<kwd>intraocular lens</kwd>
<kwd>distance vision</kwd>
<kwd>intermediate vision</kwd>
<kwd>dysphotopsias</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="11"/>
<page-count count="5"/>
<word-count count="1513"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Surgical Ophthalmology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>There are growing expectations amongst patients to be free of glasses following cataract surgery. There is now a vast array of intraocular lenses that deliver uncorrected visual acuity at various distances with fewer dysphotopsias than other types of IOL. &#x201c;Extended depth-of-focus (EDOF)&#x201d; IOLs create a single elongated focal point that extends the range of vision (<xref ref-type="bibr" rid="B1">1</xref>). In addition, fewer photic phenomena are observed compared to multifocal IOLs and trifocal IOLs (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>This mini-review should be read with reference to the &#x201c;Perspectives&#x201d; section of this book (Presbyopia-correcting intraocular lenses). The reader will then understand the reasons for the parentheses around &#x201c;EDOF&#x201d;; a more correct term being &#x201c;increased range of focus&#x201d; (IROF) IOL.</p>
<p>ISOPURE<sup>&#xae;</sup> (PhysIOL, Liege, Belgium) is a yellow hydrophobic aspheric non-diffractive IOL. Its EDOF properties are based on a polynomial surface design across the full optic providing a high amount of negative spherical aberrations, smoothly increasing from the centre to the periphery of the optic. The modification of spherical aberrations is termed isofocal technology. Isofocal optic design IOL provides excellent visual performance for far vision and functional intermediate vision with an increased range of vision.</p>
</sec>
<sec id="s2">
<title>Methodology</title>
<p>PubMed, Web of Science, Scopus, and Google Scholar searches were conducted for published research articles featuring the ISOPURE 123 IOL. A total of 23 articles were reviewed with the time interval being from 2019 to 2023. Published articles rather than conference abstracts were included as per the requirements of the publisher.</p>
</sec>
<sec id="s3">
<title>Summary of literature on visual performance</title>
<p>In patients undergoing same-day bilateral cataract surgery, the refractive aim being mini-monovision, ISOPURE<sup>&#xae;</sup> IOL provided an extended range of functional vision, up to 63 cm, resulting in useful uncorrected near vision, good uncorrected intermediate vision, and excellent uncorrected distance vision. Subjective patient satisfaction for spectacle independence and fewer dysphotopsias was high (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<p>Various studies have demonstrated the increased range of focus achieved by ISOPURE<sup>&#xae;</sup>. In non-comparative study, ISOPURE<sup>&#xae;</sup> IOL provided excellent visual performance for far vision and functional intermediate vision with an increased range of vision and good tolerance of residual refractive cylinder (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In another non-comparative study, ISOPURE<sup>&#xae;</sup> IOL, based on greater depth of focus than aspheric monofocal IOLs, offered a good option for distance and intermediate vision with fewer optical aberrations and dysphotopsias (<xref ref-type="bibr" rid="B6">6</xref>). In a randomised controlled trial comparing ISOPURE<sup>&#xae;</sup> IOL with a standard monofocal aspheric IOL, both IOLs provided excellent visual acuity and contrast sensitivity for far vision with a similar frequency of photic phenomena, but, in addition, the ISOPURE IOL improved unaided intermediate vision performance (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>In a study comparing different IROF IOLs with different mechanisms of action, there were no statistically significant differences in terms of frequency of photopic contrast sensitivity, halo, or glare perception. In patients without ocular comorbidities, the Eyhance ICB00 IOL (Johnson &amp; Johnson Vision, Wokingham, UK), the Vivinex Impress IOL (Alcon Eyecare UK Ltd, Camberley, UK), and the ISOPURE<sup>&#xae;</sup> IOL, even though based on different optical properties, provided similar results in terms of visual acuity, contrast sensitivity, and intraocular aberrations, with no influence of dysphotopsias (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>In another study comparing IROF IOLS with different optical properties, each IOL provided good distance vision without creating spontaneous complaints of photic phenomena. These IROF IOLs, including ISOPURE<sup>&#xae;</sup>, are efficient for patients wanting spectacle independence with fewer associated dysphotopsias (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>Another advantage of the isofocal optic design is that the modification of the surfaces of the isofocal lens does not have a negative impact on the refraction obtained by autorefraction compared to a standard monofocal intraocular lens (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Specific data on the occurrence of photic phenomena and optic aberrations showed that in one study, 63% had no dysphotopsias, 16% experienced glare, 16% starburst, and 5% haloes (<xref ref-type="bibr" rid="B3">3</xref>). When ISOPURE 123 was compared with a standard monofocal MICROPURE 123 IOL, the average size and intensity of halo (from pre-op 18.31 to 27.32) and glare (from pre-op 10.34 to 18.76) phenomena were similar between the two groups (<xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>In a study comparing aberrometry with a monofocal IOL (Tecnis PCB00) (<xref ref-type="bibr" rid="B6">6</xref>), the coma, spherical aberration, and higher-order aberrations were similar between groups (<italic>p</italic>=0.45). Some differences were noted in the internal spherical aberration Z (4, 0), more negative in the ISOPURE IOL but not statistically significant (<italic>p</italic>=0.024).</p>
<p>When comparing optical quality with two other extended monofocal IOLs (Tecnis Eyhance ICB00, the Hoya Vivinex Impress XY1-EM), the point spread function (PSF) (0.193 &#xb1; 0.042), intraocular low order aberration (LOA) (0.238 &#xb1; 0.110), intraocular high order aberration (HOA) (0.166 &#xb1; 0.047), intraocular spherical aberration (SA) (0.060 &#xb1; 0.035), and ocular scatter index (OSI) (1.287 &#xb1; 0.485) were similar between the groups (<italic>p</italic> = 0.184, <italic>p</italic> = 0.108, <italic>p</italic> = 0.092, <italic>p</italic> = 0.147 and <italic>p</italic> = 0.544, respectively) (<xref ref-type="bibr" rid="B8">8</xref>). Also, at 3-months post-operatively, results of Items 17 and 38 of the NEI-RQL-42 questionnaire were satisfactory in all three groups, with complete absence of glare or halo perception.</p>
</sec>
<sec id="s4" sec-type="results">
<title>Results</title>
<p>The results are summarised in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> and <xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1</bold>
</xref> and <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>. Together, these data show the number of cases analysed in each study, uncorrected and best corrected distance, intermediate and near visual acuity, and a comparison of defocus curves.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Clinical studies reporting outcomes of patients implanted with the Isopure 1.2.3. intraocular lens.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Authors<break/>(year)</th>
<th valign="top" align="left">Eyes<break/>(patients)</th>
<th valign="top" align="left">Follow-up<break/>(months)</th>
<th valign="top" align="left">Comparator<break/>
<italic>Study design</italic>
</th>
<th valign="top" align="left">Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Stodulka and Slovak (</bold>
<xref ref-type="bibr" rid="B5">5</xref>)<break/>
<bold>(2021)</bold>
</td>
<td valign="top" align="left">36<break/>(18)</td>
<td valign="top" align="left">6</td>
<td valign="top" align="left">None<break/>
<italic>Prospective</italic>
</td>
<td valign="top" align="left">Isopure IOL provides excellent CDVA and DCIVA along with high contrast sensitivity and good tolerance of residual refractive cylinder.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Bova and Vita (</bold>
<xref ref-type="bibr" rid="B6">6</xref>)<break/>
<bold>(2022)</bold>
</td>
<td valign="top" align="left">42<break/>(21)</td>
<td valign="top" align="left">12</td>
<td valign="top" align="left">Tecnis PCB00 IOL<break/>
<italic>Retrospective</italic>
<break/>
<italic>non-randomized</italic>
</td>
<td valign="top" align="left">Isopure IOL may offer a good option for the distance and intermediate vision without increasing optical aberrations and any photic phenomena.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Bernabeu-Arias et&#xa0;al. (</bold>
<xref ref-type="bibr" rid="B4">4</xref>)<break/>
<bold>(2023)</bold>
</td>
<td valign="top" align="left">183<break/>(109)</td>
<td valign="top" align="left">4</td>
<td valign="top" align="left">None<break/>
<italic>Retrosprective - prospective</italic>
</td>
<td valign="top" align="left">Isopure IOL provides excellent visual performance for far vision and functional intermediate vision with an extended range of vision. This lens is an effective option for providing functional intermediate vision and correcting aphakia.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Tomagova et&#xa0;al. (</bold>
<xref ref-type="bibr" rid="B3">3</xref>
<bold>)*</bold>
<break/>
<bold>(2023)</bold>
</td>
<td valign="top" align="left">124<break/>(62)</td>
<td valign="top" align="left">1-2</td>
<td valign="top" align="left">None<break/>
<italic>Retrospective</italic>
</td>
<td valign="top" align="left">Isopure IOL provided an extended range of functional vision (up to 63 cm) resulting in useful UNVA, good UIVA, and excellent UDVA. Subjective patient satisfaction in terms of spectacle independence and photic phenomena was high.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Lesieur and Dupreye (</bold>
<xref ref-type="bibr" rid="B9">9</xref>)<break/>
<bold>(2023)</bold>
</td>
<td valign="top" align="left">22<break/>(22)</td>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Synthesis+ IOL<break/>Lucidis IOL<break/>
<italic>Retrospective</italic>
</td>
<td valign="top" align="left">Lucidis IOL showed more efficient distance, low contrast, and near vision than Isopure and Synthesis+ IOLs. Synthesis+ IOL seems to be more efficient in intermediate vision than other groups.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Mencucci et al. (2023)</bold> (<xref ref-type="bibr" rid="B8">8</xref>)</td>
<td valign="top" align="left">12 (12, 12)</td>
<td valign="top" align="left">3</td>
<td valign="top" align="left">Retrospective non randomized (3 groups, 12 patients)</td>
<td valign="top" align="left">In conclusion, Eyhance, Impress and Isopure enhanced monofocal IOLs&#x2014;even though based on different optical profiles&#x2014;showed similar results in terms of visual outcomes, aberrometry and photic phenomena perception.</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Ang, Stodulka, Poyales</bold>
<break/>
<bold>(2023) (</bold>
<xref ref-type="bibr" rid="B7">7</xref>)</td>
<td valign="top" align="left">130<break/>(65)</td>
<td valign="top" align="left">4-6</td>
<td valign="top" align="left">Micropure 1.2.3. IOL<break/>
<italic>Prospective</italic>
<break/>
<italic>randomized</italic>
</td>
<td valign="top" align="left">Both IOLs provide excellent visual acuity and contrast sensitivity for far vision with similar photic phenomena, and the Isopure IOL improved unaided intermediate vision performance.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*bilateral implantation with mini-monovision (-0.50D); IOL, intraocular lens.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Distance and intermediate vision achieved.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fopht-03-1330335-g001.tif"/>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Near vision achieved.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fopht-03-1330335-g002.tif"/>
</fig>
<p>
<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> summarises the results from the different studies, which include comparisons with other IOLs in this category.</p>
<p>
<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref> summarises the distance and intermediate visual acuities across the studies for ISOPURE 123 IOL.</p>
<p>
<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2</bold>
</xref> and <xref ref-type="fig" rid="f3">
<bold>3</bold>
</xref> summarise the near vision achieved (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Near vision achieved.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fopht-03-1330335-g003.tif"/>
</fig>
<p>
<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref> summarises the defocus curves for ISOPURE 123 across the studies (N.B. the highest curve is a study with mini-monovision).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Defocus curves for BVI ISOPURE 123 IOL across the studies.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fopht-03-1330335-g004.tif"/>
</fig>
</sec>
<sec id="s5" sec-type="discussion">
<title>Discussion</title>
<p>The ISOPURE<sup>&#xae;</sup> IOL, which has an isofocal optic design, provides patients with a high degree of spectacle independence following cataract surgery. It provides excellent uncorrected distance vision and, in addition, provides good functional intermediate vision. With a mini-monovision refractive aim, useful near vision without spectacles is also achieved. Furthermore, there is no significant increase in the frequency of optical aberrations or dysphotopsias, meaning excellent quality of vision too.</p>
<p>Although currently there is good evidence for its visual performance, more studies are required with a greater number of participants in order to establish its true worth in providing high levels of patient satisfaction for spectacle independence and quality of vision.</p>
<p>Amongst the wide range of similar IOLs available currently, ISOPURE represents an excellent choice for surgeons and patients who seek outstanding functional vision and quality of vision with minimal spectacle dependence and photic phenomena. In addition, there is tolerance to residual astigmatism that is similar to that of a monofocal lens with pupil size up to 3.5 mm (<xref ref-type="bibr" rid="B11">11</xref>). A toric version of the IOL is awaited, as well as more data on posterior capsule opacification and YAG laser capsulotomy rates, which will become evident with long-term studies.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>EA: Conceptualization, Funding acquisition, Investigation, Project administration, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanclerz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Toto</surname> <given-names>F</given-names>
</name>
<name>
<surname>Grzybowski</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alio</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Extended depth-of-field intraocular lenses: an update</article-title>. <source>Asia Pacific J Ophthalmol</source> (<year>2020</year>) <volume>9</volume>(<issue>3</issue>):<fpage>194</fpage>&#x2013;<lpage>202</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/apo.0000000000000296</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodov</surname> <given-names>L</given-names>
</name>
<name>
<surname>Reitblat</surname> <given-names>O</given-names>
</name>
<name>
<surname>Levy</surname> <given-names>A</given-names>
</name>
<name>
<surname>Assia</surname> <given-names>EI</given-names>
</name>
<name>
<surname>Kleinmann</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Visual outcomes and patient satisfaction for trifocal, extended depth of focus and monofocal intraocular lenses</article-title>. <source>J Refract Surg Thorofare.</source> (<year>2019</year>) <volume>35</volume>(<issue>7</issue>):<page-range>434&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3928/1081597x-20190618-01</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomagova</surname> <given-names>N</given-names>
</name>
<name>
<surname>Elahi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vandekerckhove</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Clinical outcomes of a new non-diffractive extended depth-of-focus intraocular lens targeted for mini-monovision</article-title>. <source>Clin Ophthalmol</source> (<year>2023</year>) <volume>17</volume>:<page-range>981&#x2013;90</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/OPTH.S405267</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernabeu-Arias</surname> <given-names>G</given-names>
</name>
<name>
<surname>Beckers</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rinc&#xf3;n-Rosales</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Ta&#xf1;&#xe1;-Rivero</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bilbao-Calabuig</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Visual performance at different distances after implantation of an isofocal optic design intraocular lens</article-title>. <source>J Refract Surg</source> (<year>2023</year>) <volume>39</volume>(<issue>3</issue>):<page-range>150&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3928/1081597X-20230124-02</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stodulka</surname> <given-names>P</given-names>
</name>
<name>
<surname>Slovak</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Visual performance of a polynomial extended depth of focus intraocular lens</article-title>. <source>Open J Ophthalmol</source> (<year>2021</year>) <volume>11</volume>:<page-range>214&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4236/ojoph.2021.113017</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vita</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Clinical and aberrometric evaluation of a new monofocal IOL with intermediate vision improvement</article-title>. <source>J Ophthalmol</source> (<year>2022</year>) <volume>2022</volume>:<elocation-id>4119698</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2022/4119698</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ang</surname> <given-names>RET</given-names>
</name>
<name>
<surname>Stodulka</surname> <given-names>P</given-names>
</name>
<name>
<surname>Poyales</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Prospective randomized single-masked study of bilateral isofocal optic-design or monofocal intraocular lenses</article-title>. <source>Clin Ophthalmol</source> (<year>2023</year>) <volume>17</volume>:<page-range>2231&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2147/OPTH.S425352</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mencucci</surname> <given-names>R</given-names>
</name>
<name>
<surname>Morelli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cennamo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Roszkowska</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Favuzza</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Enhanced monofocal intraocular lenses: A retrospective, comparative study between three different models</article-title>. <source>J Clin Med</source> (<year>2023</year>) <volume>12</volume>(<issue>10</issue>):<elocation-id>3588</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm12103588</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesieur</surname> <given-names>G</given-names>
</name>
<name>
<surname>Dupeyre</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>A comparative evaluation of three extended depth of focus intraocular lenses</article-title>. <source>Eur J Ophthalmol</source> (<year>2023</year>) <volume>5</volume>:<elocation-id>11206721231154818</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/11206721231154818</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez-Sanz</surname> <given-names>L</given-names>
</name>
<name>
<surname>Charbel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Poyales</surname> <given-names>F</given-names>
</name>
<name>
<surname>Garz&#xf3;n</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Influence of isofocal intraocular lenses on objective refraction based on autorefraction and aberrometry</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source> (<year>2023</year>) <volume>261</volume>(<issue>10</issue>):<page-range>2863&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00417-023-06102</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>P&#xe9;rez-Sanz</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vega</surname> <given-names>F</given-names>
</name>
<name>
<surname>Azor</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cuellar</surname> <given-names>F&#xe1;tima</given-names>
</name>
<name>
<surname>Mill&#xe1;n</surname> <given-names>Mar&#xed;a</given-names>
</name>
<name>
<surname>Garz&#xf3;n</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Tolerance to residual astigmatism of an isofocal intraocular lens</article-title>. <source>Graefe's Arch Clin Exp Ophthalmol</source> (<year>2023</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00417-023-06305-9</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>